- Home
- NCV vs MREO Comparison
NCV vs MREO Comparison
Compare NCV & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCV
- MREO
- Stock Information
- Founded
- NCV 2003
- MREO 2015
- Country
- NCV United States
- MREO United Kingdom
- Employees
- NCV N/A
- MREO N/A
- Industry
- NCV Finance Companies
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- NCV Finance
- MREO Health Care
- Exchange
- NCV Nasdaq
- MREO Nasdaq
- Market Cap
- NCV 350.4M
- MREO 311.8M
- IPO Year
- NCV N/A
- MREO N/A
- Fundamental
- Price
- NCV $15.28
- MREO $2.21
- Analyst Decision
- NCV
- MREO Strong Buy
- Analyst Count
- NCV 0
- MREO 5
- Target Price
- NCV N/A
- MREO $7.40
- AVG Volume (30 Days)
- NCV 405.1K
- MREO 1.4M
- Earning Date
- NCV 01-01-0001
- MREO 11-11-2025
- Dividend Yield
- NCV 12.48%
- MREO N/A
- EPS Growth
- NCV N/A
- MREO N/A
- EPS
- NCV N/A
- MREO N/A
- Revenue
- NCV N/A
- MREO $500,000.00
- Revenue This Year
- NCV N/A
- MREO N/A
- Revenue Next Year
- NCV N/A
- MREO $72.16
- P/E Ratio
- NCV N/A
- MREO N/A
- Revenue Growth
- NCV N/A
- MREO N/A
- 52 Week Low
- NCV $2.84
- MREO $1.47
- 52 Week High
- NCV $3.59
- MREO $4.72
- Technical
- Relative Strength Index (RSI)
- NCV 51.50
- MREO 65.68
- Support Level
- NCV $15.19
- MREO $1.94
- Resistance Level
- NCV $15.69
- MREO $2.28
- Average True Range (ATR)
- NCV 0.22
- MREO 0.12
- MACD
- NCV -0.04
- MREO 0.02
- Stochastic Oscillator
- NCV 32.88
- MREO 79.48
About NCV Virtus Convertible & Income Fund of Beneficial Interest
Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and high current income. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).